Pharmaceutical use of argininyl fructosy glucose

An arginine disoside and drug technology, which can be applied to drug combinations, medical preparations containing active ingredients, and pharmaceutical formulations, etc., can solve the problem that the pharmacological activity of non-saponin ingredients is rarely studied, and achieve good social benefits, The effect of protecting liver cells and reducing apoptosis

Active Publication Date: 2019-08-16
DALIAN NATIONALITIES UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few studies on the pharmacolo...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of argininyl fructosy glucose
  • Pharmaceutical use of argininyl fructosy glucose
  • Pharmaceutical use of argininyl fructosy glucose

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The preparation of embodiment 1 medicine

[0025] Preparation of capsules: 100 g of arginine diglucoside, add appropriate amount of starch and lactose, mix uniformly by equal addition method, after passing the inspection, fill capsules, pack, and obtain the finished product. 400 capsules were prepared, each containing 250 mg of arginine diglucoside.

Embodiment 2

[0026] The preparation of embodiment 2 medicine

[0027] Preparation of tablets: Add 100 g of arginine diglucoside, add appropriate amount of starch, 1.5 g of magnesium stearate, mix well, and press into tablets to get ready. Each tablet weighs 0.3 g, and each tablet contains 250 mg of arginine diglucoside.

Embodiment 3

[0028] The preparation of embodiment 3 medicine

[0029] Preparation of immediate-release pellets: 3 parts of arginine diglucoside, 7 parts of microcrystalline cellulose, mix evenly, add 7 parts of 70% ethanol, knead continuously, make soft material, extrude through extruder sieve plate to have the same diameter , Smooth and dense strips, after shearing, rolled into pellets, baked at 40-50°C for 3-4 hours, sieved, and took 20-30 mesh pellets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical use of argininyl fructosy glucose, and belongs to the field of research and development of pharmaceutical products. The pharmaceutical use refers to application of the argininyl fructosy glucose, as an active ingredient, in preparation of drugs for treating or preventing acute hepatic failure. The acute hepatic failure is oxidative stress injury caused by the combination of lipopolysaccharide and D-galactosamine, liver cells are protected from injuries, and apoptosis caused by LPS/D-GalN is reduced. The purity of the argininyl fructosy glucose is 80-99.99%. The argininyl fructosy glucose is applied to prevention or treatment of the acute hepatic failure for the first time, so that a new raw material is provided for the preparation of the drugs for the acute hepatic failure, and a new method is also provided for the prevention and treatment of the acute liver failure.

Description

technical field [0001] The invention discloses a medicinal use of arginine diglucoside, which belongs to the medical technical field of novel biological activity of monomeric compounds of traditional Chinese medicines. Background technique [0002] LPS is lipopolysaccharide, which is one of the components of the cell wall of Gram-negative bacteria. It can induce many diseases, cause endotoxic shock, inflammatory diseases, and multiple organ damage. It is related to the occurrence of tumor diseases, but LPS used alone in Specificity for liver injury is low. D-GalN is D-galactosamine, which is a hepatocyte uridine phosphate interfering agent, which can cause metabolic disorders, induce inflammation and diffuse necrosis of the liver, and can cause fulminant hepatic failure when used in large doses. The combination of lipopolysaccharide and D-galactosamine (LPS / D-GalN) can increase the specificity of LPS in liver injury and cause severe hepatitis. This model simulates fulminant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7016A61P1/16A23L33/175A23L33/125
CPCA61K31/7016A61P1/16A23L33/175A23L33/125A61K31/7028
Inventor 李珂珂弓晓杰
Owner DALIAN NATIONALITIES UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap